8-KMaterial AgreementsSecurities & ListingOther Events+1

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jan 26, 2015)

Filed January 26, 2015For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed a Form 8-K on January 26, 2015, reporting on a significant underwritten public offering of its common stock. The company successfully raised approximately $431.6 million in net proceeds from the sale of 4,736,842 shares at an offering price of $95.00 per share. This offering was conducted under an existing shelf registration statement, indicating a well-established process for capital raises. In addition to the public offering, the filing details transactions with Genzyme Corporation, a significant shareholder. Genzyme exercised specific rights under an existing investor agreement to purchase additional shares, acquiring 196,251 shares for approximately $18.3 million under its "Compensatory Right" and another 647,448 shares for approximately $61.5 million under its "Offering Right" in connection with the public offering. These transactions allowed Genzyme to maintain its ownership percentage of approximately 12% of Alnylam's outstanding common stock. The funds raised from the public offering will likely bolster Alnylam's financial position, supporting its ongoing research and development activities in the RNAi therapeutics space.

Key Highlights

  • 1Alnylam Pharmaceuticals successfully completed a public offering of 4,736,842 shares of common stock on January 26, 2015.
  • 2The offering raised approximately $431.6 million in net proceeds for the company.
  • 3The shares were offered at $95.00 per share, with underwriters purchasing them at $91.20 per share.
  • 4The company granted underwriters an option to purchase an additional 710,526 shares.
  • 5Genzyme Corporation exercised its "Compensatory Right" to purchase 196,251 shares for approximately $18.3 million.
  • 6Genzyme also exercised its "Offering Right" to purchase 647,448 shares for approximately $61.5 million in connection with the public offering, maintaining its ~12% ownership.
  • 7The offering was conducted under a previously filed shelf registration statement.

Frequently Asked Questions

The primary purpose of this Form 8-K was to report on the entry into a material definitive agreement, specifically the underwriting agreement for a public offering of Alnylam Pharmaceuticals' common stock, and to disclose related transactions with Genzyme Corporation.

Alnylam Pharmaceuticals expected to receive net proceeds of approximately $431.6 million from the public offering, after accounting for underwriting discounts and estimated expenses.

Genzyme, a significant shareholder, exercised two specific rights: the "Compensatory Right" to purchase shares issued for compensation purposes and the "Offering Right" to purchase shares in connection with the public offering. These actions allowed Genzyme to maintain its ownership percentage in Alnylam.

No, the shares purchased by Genzyme were in private placements directly from the company, separate from the public offering, though Genzyme exercised its "Offering Right" in conjunction with the public offering. These were issued under an exemption from registration.